New Mexico Tech Monitor
SEE OTHER BRANDS

Exploring the science and technology news of New Mexico

New Mexico Tech Monitor: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Tech Monitor.

Press releases published on May 8, 2025

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non- …

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and …

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date   CALM-CAH Phase 3 Study of Atumelnant for the Treatment of Adults with Congenital Adrenal …

Sprout Social Announces First Quarter 2025 Financial Results

Sprout Social Announces First Quarter 2025 Financial Results

CHICAGO, May 08, 2025 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its first quarter ended March …

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025 …

Magnite to Participate in Upcoming Financial Conferences

Magnite to Participate in Upcoming Financial Conferences

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Magnite (Nasdaq: MGNI), the largest independent sell-side advertising company, today announced that members of its executive team will participate and host in-person investor meetings at the following financial …

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025; Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter of 2026 with no debt Conference call …

Varonis to Present at Upcoming Investor Conferences

Varonis to Present at Upcoming Investor Conferences

MIAMI, May 08, 2025 (GLOBE NEWSWIRE) -- Varonis Systems, Inc. (Nasdaq: VRNS), the leader in data security, announced its participation at the following upcoming conferences: The J.P. Morgan 53rd Annual Global Technology, Media and Communications Conference …

Senseonics Holdings, Inc. Reports First Quarter Financial Results

Senseonics Holdings, Inc. Reports First Quarter Financial Results

Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor (CGM); twiist with Eversense 365 launch expected in Q3 …

AvePoint Announces First Quarter 2025 Financial Results

AvePoint Announces First Quarter 2025 Financial Results

First quarter SaaS revenue of $68.9 million, representing 34% year-over-year growth, 37% on a constant currency basis First quarter Total revenue of $93.1 million, representing 25% year-over-year growth, 27% on a constant currency basis Total ARR of $345.5 …

Cytek Biosciences Reports First Quarter 2025 Financial Results

Cytek Biosciences Reports First Quarter 2025 Financial Results

FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First …

Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates

Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates

Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with …

Lantronix Reports Results for Third Quarter of Fiscal 2025

Lantronix Reports Results for Third Quarter of Fiscal 2025

Third Quarter Net Revenue of $28.5 Million Third Quarter GAAP EPS of ($0.10) Third Quarter Non-GAAP EPS of $0.03 IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for the Internet of …

TELA Bio Reports First Quarter 2025 Financial Results

TELA Bio Reports First Quarter 2025 Financial Results

MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended …

CEA Industries Inc. Provides Update on Fat Panda Acquisition 

CEA Industries Inc. Provides Update on Fat Panda Acquisition 

Transaction reflects CEA Industries’ strategic evolution and pivotal entry into attractive high-growth vape market Accelerates Fat Panda’s growth initiatives as central Canada’s largest retailer and manufacturer of e-cigarettes, vape devices and e-liquids …

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded intellectual property portfolio with second patent covering …

SIGA Reports Financial Results for Three Months Ended March 31, 2025

SIGA Reports Financial Results for Three Months Ended March 31, 2025

Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March $94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025 Corporate Update Conference Call Today at 4:30 PM ET NEW …

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials …

Oculis Reports Q1 2025 Financial Results and Provides Company Update

Oculis Reports Q1 2025 Financial Results and Provides Company Update

The recent R…

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system ( …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service